Global Search

Search articles, concepts, and chapters

Invest Ophthalmol Vis SciJuly 201725 citations

Inhibition of Monocyte Chemoattractant Protein 1 Prevents Conjunctival Fibrosis in an Experimental Model of Glaucoma Filtration Surgery.

Chong Rachel Shujuan, Lee Ying Shi, Chu Stephanie Wai Ling, Toh Li Zhen, Wong Tina Tzee Ling


AI Summary

MCP-1 inhibition in mice prevented conjunctival fibrosis after glaucoma surgery, showing superior bleb survival and less cellular toxicity than MMC. This suggests a safer antifibrotic alternative for patients.

Abstract

Purpose

To evaluate the effect of treatment with monocyte chemoattractant protein-1 receptor inhibitor (MCP-Ri) to maintain bleb survival and prevent fibrosis in an experimental model of glaucoma filtration surgery (GFS).

Methods

GFS was performed on one eye of C57/Bl6 mice (n = 36) that was treated with MCP-Ri, mitomycin-C (MMC), or vehicle at the time of surgery. Real-time polymerase chain reaction was used to evaluate conjunctival expression of monocyte chemoattractant protein-1 (MCP-1), TGFB1, TGFB2, collagen 1a1 (Col1a1), sparc (Sparc), and fibronectin at 2 and 7 days following surgery. Anterior segment slit-lamp examination, optical coherence tomography, and confocal microscopy were performed in vivo at day 14. Eyes were processed for immunohistochemical staining of F4/80, a monocyte-macrophage marker, at day 2. In vitro experiments were also performed to compare the effect of MMC, MCP-Ri, and vehicle on the viability of mouse Tenon's fibroblasts.

Results

Treatment with MCP-Ri results in a greater reduction in the percentage of F4/80-positive cells in conjunctival blebs and lesser MCP-1 gene expression following experimental GFS than MMC or control. Both MMC and MCP-Ri reduced Col1a1 and Sparc expression, but not fibronectin. TGFB1 decreased with MCP-Ri but not MMC; MMC but not MCP-Ri reduced TGFB2. MMC and MCP-Ri treatment resulted in the preservation of bleb height at day 14, as compared to control. MCP-Ri was less toxic to mouse Tenon's fibroblasts in comparison with MMC.

Conclusions

Targeting MCP-1 results in prolonged bleb survival following experimental GFS with less cellular toxicity as compared to MMC. MCP inhibition could provide a safer alternative to conventional antifibrotic adjunctive treatments in GFS.


MeSH Terms

AnimalsAntifibrinolytic AgentsCell SurvivalChemokine CCL2CollagenConjunctivaDisease Models, AnimalEnzyme InhibitorsFibroblastsFibronectinsFibrosisFiltering SurgeryGlaucomaGlaucoma Drainage ImplantsMiceMice, Inbred C57BLMitomycinOsteonectinReceptors, CCR2Transforming Growth Factor beta

Key Concepts6

Treatment with monocyte chemoattractant protein-1 receptor inhibitor (MCP-Ri) resulted in a greater reduction in the percentage of F4/80-positive cells in conjunctival blebs and lesser MCP-1 gene expression following experimental glaucoma filtration surgery (GFS) in C57/Bl6 mice (n=36) compared to mitomycin-C (MMC) or control.

MechanismBasic ScienceExperimental Animal Studyn=36 C57/Bl6 miceCh2Ch41

Both mitomycin-C (MMC) and monocyte chemoattractant protein-1 receptor inhibitor (MCP-Ri) reduced collagen 1a1 (Col1a1) and sparc (Sparc) expression, but not fibronectin, following experimental glaucoma filtration surgery (GFS) in C57/Bl6 mice (n=36).

MechanismBasic ScienceExperimental Animal Studyn=36 C57/Bl6 miceCh2Ch41

TGFB1 expression decreased with monocyte chemoattractant protein-1 receptor inhibitor (MCP-Ri) but not mitomycin-C (MMC), while MMC but not MCP-Ri reduced TGFB2 expression following experimental glaucoma filtration surgery (GFS) in C57/Bl6 mice (n=36).

MechanismBasic ScienceExperimental Animal Studyn=36 C57/Bl6 miceCh2Ch41

Treatment with mitomycin-C (MMC) and monocyte chemoattractant protein-1 receptor inhibitor (MCP-Ri) resulted in the preservation of bleb height at day 14 following experimental glaucoma filtration surgery (GFS) in C57/Bl6 mice (n=36), as compared to control.

TreatmentBasic ScienceExperimental Animal Studyn=36 C57/Bl6 miceCh41

Monocyte chemoattractant protein-1 receptor inhibitor (MCP-Ri) was less toxic to mouse Tenon's fibroblasts in vitro compared to mitomycin-C (MMC).

MechanismBasic ScienceIn Vitro Studyn=In vitro experimentsCh2Ch41

Targeting monocyte chemoattractant protein-1 (MCP-1) with MCP-Ri could provide a safer alternative to conventional antifibrotic adjunctive treatments in glaucoma filtration surgery (GFS), due to prolonged bleb survival with less cellular toxicity compared to mitomycin-C (MMC) in an experimental model of GFS in C57/Bl6 mice (n=36).

TreatmentBasic ScienceExperimental Animal Studyn=36 C57/Bl6 miceCh2Ch41

Is this article assigned to the wrong chapter(s)? Let us know.